Stargardt disease 4

disease
On this page

Also known as PROM1 Stargardt diseaseStargardt disease caused by mutation in PROM1Stargardt disease type 4STGD4

Summary

Stargardt disease 4 (MONDO:0011370) is a disease with 1 cohort gene and 1 clinical trial.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 129
  • Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameStargardt disease 4
Mondo IDMONDO:0011370
MeSHC535521
OMIM603786
DOIDDOID:0061239
UMLSC1863534
MedGen355004
GARD0015359
Is cancer (heuristic)no

Also known as: PROM1 Stargardt disease · Stargardt disease 4 · Stargardt disease caused by mutation in PROM1 · Stargardt disease type 4 · STGD4

Data availability: 129 ClinVar variants.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationmacular degenerationStargardt diseaseStargardt disease 4

Related subtypes (3): severe early-childhood-onset retinal dystrophy, Stargardt disease 3, Stargardt disease 5

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

129 retrieved; paginated sample, class counts are floors:

60 conflicting classifications of pathogenicity, 45 uncertain significance, 12 benign, 5 pathogenic/likely pathogenic, 3 benign/likely benign, 2 pathogenic, 2 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
253326NM_006017.3(PROM1):c.1157T>A (p.Leu386Ter)PROM1Pathogeniccriteria provided, multiple submitters, no conflicts
3249011NM_006017.3(PROM1):c.2378T>A (p.Leu793Ter)PROM1Pathogenic/Likely pathogenicno assertion criteria provided
3780492NM_006017.3(PROM1):c.154del (p.Ile52fs)PROM1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
402237NM_006017.3(PROM1):c.622del (p.Thr208fs)PROM1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
5610NM_006017.3(PROM1):c.1117C>T (p.Arg373Cys)PROM1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
809626NM_006017.3(PROM1):c.1142-1G>APROM1Pathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
932145NM_006017.3(PROM1):c.734T>C (p.Leu245Pro)PROM1Pathogenicno assertion criteria provided
3251979NM_006017.3(PROM1):c.1984-1G>APROM1Likely pathogeniccriteria provided, single submitter
4686710NM_006017.3(PROM1):c.484_485del (p.Leu162fs)PROM1Likely pathogeniccriteria provided, single submitter
167535NM_006017.3(PROM1):c.1497C>T (p.Ile499=)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
191189NM_006017.3(PROM1):c.604C>G (p.Arg202Gly)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
194072NM_006017.3(PROM1):c.1345G>A (p.Val449Met)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
236524NM_006017.3(PROM1):c.1632G>T (p.Gly544=)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
287074NM_006017.3(PROM1):c.1928C>G (p.Ala643Gly)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
289314NM_006017.3(PROM1):c.868A>C (p.Ser290Arg)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
289616NM_006017.3(PROM1):c.2271C>T (p.Ile757=)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347965NM_006017.3(PROM1):c.*1052G>APROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347967NM_006017.3(PROM1):c.*684C>TPROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347971NM_006017.3(PROM1):c.2578A>G (p.Thr860Ala)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347972NM_006017.3(PROM1):c.2551G>A (p.Val851Ile)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347977NM_006017.3(PROM1):c.2364C>T (p.Ile788=)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347978NM_006017.3(PROM1):c.2309C>A (p.Pro770His)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347979NM_006017.3(PROM1):c.2284A>G (p.Ser762Gly)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347981NM_006017.3(PROM1):c.2211+7C>TPROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347984NM_006017.3(PROM1):c.1911+14G>APROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347987NM_006017.3(PROM1):c.1683-3C>TPROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347988NM_006017.3(PROM1):c.1579-6T>CPROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347989NM_006017.3(PROM1):c.1578+9G>CPROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347990NM_006017.3(PROM1):c.1576C>T (p.Arg526Trp)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
347991NM_006017.3(PROM1):c.1491G>T (p.Leu497Phe)PROM1Conflicting classifications of pathogenicitycriteria provided, conflicting classifications

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 4 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PROM1Orphanet:1872Cone rod dystrophy
PROM1Orphanet:319640Retinal macular dystrophy type 2
PROM1Orphanet:791Retinitis pigmentosa
PROM1Orphanet:827Stargardt disease

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
PROM1HGNC:9454ENSG00000007062O43490Prominin-1clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
PROM1Prominin-1May play a role in cell differentiation, proliferation and apoptosis.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
PROM1Other/UnknownnoProminin

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
bronchial epithelial cell1
bronchus1
epithelium of bronchus1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
PROM1252broadmarkerbronchial epithelial cell, epithelium of bronchus, bronchus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PROM13,302

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
PROM1O4349085.68

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Developmental Lineage of Pancreatic Ductal Cells1228.4×0.004PROM1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
glomerular parietal epithelial cell differentiation18426.0×6e-04PROM1
positive regulation of nephron tubule epithelial cell differentiation15617.3×6e-04PROM1
camera-type eye photoreceptor cell differentiation13370.4×7e-04PROM1
retina morphogenesis in camera-type eye11872.4×9e-04PROM1
podocyte differentiation11404.3×1e-03PROM1
retina layer formation1648.1×0.002PROM1
photoreceptor cell maintenance1358.6×0.003PROM1

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
PROM100

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1PROM1

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
PROM10

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04281732Not specifiedUNKNOWNVisual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision